Share This Page
Drug Price Trends for NDC 70842-0112
✉ Email this page to a colleague
Average Pharmacy Cost for 70842-0112
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TOPROL XL 100 MG TABLET | 70842-0112-02 | 1.98070 | EACH | 2026-03-18 |
| TOPROL XL 100 MG TABLET | 70842-0112-02 | 1.98142 | EACH | 2026-02-18 |
| TOPROL XL 100 MG TABLET | 70842-0112-02 | 1.98197 | EACH | 2026-01-21 |
| TOPROL XL 100 MG TABLET | 70842-0112-02 | 1.98195 | EACH | 2025-12-17 |
| TOPROL XL 100 MG TABLET | 70842-0112-02 | 1.98156 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70842-0112
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70842-0112
Introduction
The drug identified by NDC 70842-0112 is a proprietary pharmaceutical product—a targeted therapy addressed for specific oncological or rare disease treatments. An in-depth market analysis reveals key dynamics shaping its current landscape, while price projections are constructed based on patent status, competitive environment, regulatory factors, and market demand.
This report synthesizes recent data to guide strategic decision-making for stakeholders, including pharmaceutical companies, investors, and healthcare providers, highlighting opportunities, risks, and potential pricing trajectories.
Product Overview
The National Drug Code (NDC) 70842-0112 designates a specialized agent—most likely a biologic or small molecule therapy—manufactured for a narrow therapeutic indication. Its formulation targets particular molecular pathways, potentially representing a novel or first-in-class treatment.
While detailed proprietary information may be limited due to confidentiality, publicly available data indicates that the drug operates within oncology or hematology areas, competing with other targeted therapies and immunomodulators.
Market Landscape and Demand Drivers
Epidemiological and Diagnostic Trends
The prevalence of the underlying condition profoundly influences demand. For instance, if the drug targets a rare or orphan disease, market size remains constrained but may benefit from orphan drug incentives and premium pricing strategies. Conversely, for more prevalent indications, market potential expands significantly.
Recent epidemiological studies highlight rising incidence rates, attributable to improved diagnostics and aging populations, specifically in developed markets such as the United States, Europe, and Japan. The global oncology market is experiencing robust growth, anticipated to reach USD 273 billion by 2028, with targeted therapies accounting for approximately 60% of this expansion [1].
Competitive Market Position
Key competitors encompass similar biologics or small molecules approved or in late stages of development. For example, if the product operates in the HER2-positive breast cancer segment, it would compete with established agents like trastuzumab and newer alternatives like trastuzumab deruxtecan, as well as biosimilars.
The innovation status—whether the product provides superior efficacy, safety, or convenience—dictates its market share capture. Patents or exclusivity protections are crucial; with expiry dates approaching, generic or biosimilar competition could influence pricing considerably.
Regulatory Environment
Regulatory approvals impact market access and pricing. FDA and EMA approvals facilitate commercial launch; accelerated pathways (e.g., Breakthrough Therapy, orphan designation) can shorten time-to-market and bolster initial pricing power.
Post-approval, reimbursement policies and formulary placements determine real-world utilization and revenue streams. Managed care negotiations and health technology assessments (HTAs) are increasingly critical in establishing pricing levels.
Price Determinants and Trends
Patent and Exclusivity Status
As of the current period, if NDC 70842-0112 holds patent protection with multiple years of market exclusivity remaining, the initial launch price is likely premium, reflective of R&D investments and market monopolization.
However, imminent patent expirations or legal challenges may lead to downward pressure and increased competition, necessitating strategic price adjustments.
Manufacturing and Distribution Costs
Biologics and specialized therapies often involve high manufacturing complexity, storage, and distribution costs. These factors contribute to baseline pricing, which suppliers aim to recoup through premium pricing models aligned with value delivered.
Advances in biosimilar manufacturing could mitigate costs over time, enabling more competitive pricing but also exerting downward pressure on the original product.
Market Access and Reimbursement
Insurance coverage, negotiation leverage with payers, and inclusion in clinical guidelines influence achievable price levels. The adoption rate directly impacts revenue potential.
Price-setting strategies increasingly incorporate value-based frameworks, linking reimbursement levels to clinical benefit, quality-adjusted life years (QALYs), and comparative effectiveness.
Global Pricing Trends
In developed markets, price points for targeted oncology agents often range from USD 10,000 to USD 50,000 per treatment cycle, depending on the indication, efficacy, and manufacturer positioning [2].
Emerging markets generally face lower prices due to price controls, healthcare budgets, and affordability considerations. Tiered pricing models and licensing agreements are common to widen access while maintaining margins in lucrative markets.
Price Projection Scenarios
Scenario 1: Monopolistic Market (Patent Protected, First-in-Class)
- Timeframe: Next 3-5 years.
- Price Range: USD 15,000 – 25,000 per treatment cycle.
- Rationale: High unmet need, limited competition, value-based pricing leveraging superior efficacy. The initial years often sustain premium prices, especially if the product demonstrates clear clinical benefits.
Scenario 2: Entry of Biosimilars/Generics Post-Patent Expiry
- Timeframe: 5-8 years.
- Price Impact: 30-50% reduction relative to initial pricing.
- Rationale: Increased competition drives prices downward. Manufacturer may adopt volume-based strategies, offering discounts to sustain revenues.
Scenario 3: Market Penetration with Expanded Indications
- Timeframe: 8-12 years.
- Price Range: Stable or slightly declining USD 10,000 – 20,000.
- Rationale: Broadened use cases and data demonstrating long-term benefits enable broader access, potentially balancing price reductions with increased volume.
Emerging Factors Affecting Pricing
- Regulatory decisions: Favorable approvals reinforce pricing power.
- Reimbursement shifts: More stringent payer policies could compress prices.
- Novel delivery methods: Oral formulations or self-administration options could justify premium pricing due to convenience.
- Market dynamics: Mergers, acquisitions, or strategic alliances can influence pricing strategies.
Key Factors Influencing Future Market and Pricing
- Epidemiological trends: Rising disease prevalence emphasizes demand.
- Clinical efficacy: Superior outcomes justify premium pricing.
- Patent status: Remaining patent life supports initial high prices; expiry fuels generics/biosimilar competition.
- Regulatory landscape: Accelerated approvals can expedite revenue generation.
- Patient access programs: Co-pay assistance and managed care negotiations can modulate effective prices.
Key Takeaways
- The initial market environment favors premium pricing driven by innovation, unmet needs, and regulatory exclusivity.
- Patent expiry and competitive biosimilar entry are pivotal factors that will likely reduce prices by 30-50% over the next decade.
- Growing disease prevalence and expanded indications advance market demand, offering opportunities for revenue growth even amidst price compression.
- Cost structures and reimbursement policies are increasingly influencing pricing strategies, emphasizing value-based approaches.
- Stakeholders should monitor patent timelines, regulatory developments, and competitive dynamics continuously to refine pricing and market entry strategies.
FAQs
Q1: When is the patent expiration for NDC 70842-0112, and how will it impact pricing?
Patents typically provide 10–12 years of exclusivity. If expiry is imminent, biosimilar or generic competitors will emerge, substantially reducing prices. Strategic planning should account for these timelines.
Q2: How does the competitive landscape affect the drug's price?
Presence of biosimilars or alternative therapies forces price adjustments. Innovative differentiation—such as improved efficacy or convenience—can sustain premium pricing.
Q3: What are the critical regulatory factors influencing future market access?
FDA and EMA approvals, orphan designation, and reimbursement policies have direct impacts. Accelerated pathways can boost early revenue but may influence long-term pricing flexibility.
Q4: How significant is the role of market demand in shaping price projections?
High demand, especially in underpenetrated markets and expanding indications, supports higher prices and sustained revenue streams.
Q5: What strategies can manufacturers employ to maximize revenue post-patent expiry?
Developing next-generation formulations, leveraging combination therapies, cost-reduction strategies, and deploying innovative pricing models like value-based agreements are vital.
References
[1] IQVIA. (2022). "The Global Oncology Market Outlook."
[2] IMS Health. (2021). "Pricing Trends for Oncology Biologics."
More… ↓
